119-hr3493

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3493 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
 H. R. 3493

 To reduce prescription drug prices by aligning U.S. prices with 
 international benchmarks.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 May 19, 2025

 Mr. Khanna (for himself, Mrs. Luna, Ms. Kaptur, and Mr. Biggs of 
 Arizona) introduced the following bill; which was referred to the 
Committee on Energy and Commerce, and in addition to the Committees on 
 Ways and Means, and the Judiciary, for a period to be subsequently 
 determined by the Speaker, in each case for consideration of such 
 provisions as fall within the jurisdiction of the committee concerned

_______________________________________________________________________

 A BILL

 To reduce prescription drug prices by aligning U.S. prices with 
 international benchmarks.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``Global Fairness in Drug Pricing 
Act''.

SEC. 2. DRUG PRICING.

    (a) Most-favored Nation Price Targets.--Not later than 30 days 
after the date of enactment of this Act, the Secretary of Health and 
Human Services shall, in coordination with the Administrator of the 
Centers for Medicare & Medicaid Services and other heads of relevant 
Federal agencies--propose a rulemaking plan to impose most-favored-
nation price targets to pharmaceutical manufacturers to ensure that 
prices for pharmaceutical products paid by patients in the United 
States are comparable to the prices for such products paid by 
comparably developed countries.

    (b) Importation by Individuals.--The Secretary of Health and Human 
Services shall certify to Congress that importation under 

section 804

    (j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384

    (j) ) 
will pose no risk to the health and safety of the public and will 
result in a significant reduction in the cost of prescription drugs to 
the American patients in the United States; and the Secretary of Health 
and Human Services shall take action under 

section 804

    (j)

    (2)
        (B) of such 
Act to describe circumstances under which waivers will be consistently 
granted to individuals to import prescription drugs, on a case-by-case 
basis, from developed countries with low-cost prescription drugs.
            (c) Enforcement Actions.--The Attorney General and the Chair of the 
Federal Trade Commission shall, to the extent consistent with law, 
undertake enforcement action against any anticompetitive practices by 
pharmaceutical manufacturers, including through enforcement of sections 
1 and 2 of the Sherman Act (15 U.S.C. 1, 2) and 

section 5 of the 
Federal Trade Commission Act (15 U.S.C. 45), as appropriate.
            (d) Programs Enabling Direct-to-Consumer Purchases.--To the extent 
permitted by law, the Secretary of Health and Human Services shall 
facilitate direct-to-consumer purchasing programs for pharmaceutical 
manufacturers that sell their pharmaceutical products to patients in 
the United States at the prices determined through the rulemaking under 
subsection

    (a) .

    (e) Study of Unreasonable or Discriminatory Behaviors of 
Manufacturers.--The Secretary of Commerce and the United States Trade 
Representative shall conduct a study to determine whether any act, 
policy, or practice by pharmaceutical manufacturers constitutes 
unreasonable or discriminatory behavior that--

    (1) impairs national security;

    (2) forces patients in the United States to subsidize 
 global pharmaceutical research and development; or

    (3) involves suppression of drug prices in foreign markets 
 below fair market value.
The findings of such a study shall be submitted in a report to Congress 
not later than 180 days after the date of the enactment of this Act.
 <all>